Stocktwits on MSN
CAPR stock in focus: Ex-exec eyed for FDA role says drug approvals are not 'best-in-class' signals
Hemmati is reportedly being considered for a leadership role at the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research. ・The regulatory spotlight has intensified ...
Below is Validea's guru fundamental report for CAPRICOR THERAPEUTICS INC (CAPR). Of the 22 guru strategies we follow, CAPR rates highest using our Small-Cap Growth Investor model based on the ...
Below is Validea's guru fundamental report for CAPRICOR THERAPEUTICS INC (CAPR). Of the 22 guru strategies we follow, CAPR rates highest using our P/B Growth Investor model based on the published ...
Capricor Therapeutics (CAPR) has made significant progress in advancing the use of its cell therapy, known as CAP-1002, which is being developed for the treatment of patients with Duchenne Muscular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results